Publications & Posters
Publications & Posters
| Title | Author | Reference | Sample Type | Patient Count | Primary Endpoint | Treatment Type |
|---|---|---|---|---|---|---|
| {{pub.author}} | {{pub.journal}}, |
{{sample}}
|
{{pub.patients}} |
{{endpoint}}
|
{{pub.treatment}} |
| Title | Author | Reference | Sample Type | Patient Count | Primary Endpoint | Treatment Type |
|---|---|---|---|---|---|---|
| {{pub.author}} | {{pub.journal}}, |
{{sample}}
|
{{pub.patients}} | {{endpoint}} |
{{pub.treatment}} |
Prolaris® Validated Weighted Algorithm - combines molecular and clinical features:
Hover Over Each Section to Learn More
Combined Clinical Risk Score
CCR is used to predict outcomes such as Disease Specific Mortality (DSM) and Metastasis (METs). Clinical decisions should be based on DSM and METs risk shown on the Prolaris results.
Weighted elements were validated in Cuzick et al. (2015)
- Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer. 2015;113(3):382-389. Doi: 10.1038/bjc.2015.
Cancer of the Prostate Risk Assessment Score
The score is calculated using points assigned to: age at diagnosis, PSA at diagnosis, Gleason score of the biopsy, clinical stage and percent of biopsy cores involved with cancer. The scale of this score is 0-10.
https://urology.ucsf.edu/research/cancer/prostate-cancer-risk-assessment-and-the-ucsf-capra-score
Cell Cycle Progression Score
CCP measures the activity of the cell cycle progression genes and is the molecular component of the Prolaris test. Do not use CCP alone for clinical decisions. The approximate scale of this score is about 1-11.
Prolaris® provides similar risks for different cohorts, demonstrating reproducibility
Compare risks curves using CCR for Cuzick et al 2012 and Cuzick et al 2015:
Red line based on Cuzick et al 2015 cohort; green line on Cuzick et al 2012 cohort. Ticks represent observed CCR scores.
- Cuzick J, et al. Prognostic value of a cell cycle progression
signature for prostate cancer death in a conservatively managed needle biopsy cohort. British
Journal of Cancer. 2012; 106(6):1095-1099. doi:10.1038/bjc.2012.39
- Cuzick J, et al. Validation of an RNA cell cycle progression score for predicting death from
prostate cancer in a conservatively managed needle biopsy cohort. British Journal of Cancer.
2015;113(3):382-389. Doi: 10.1038/bjc.2015.223